At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KTTA Pasithea Therapeutics Corp.
Market Closed 01-10 16:00:00 EST
2.56
-0.24
-8.57%
盘后2.62
+0.06+2.34%
16:00 EST
High2.77
Low2.52
Vol18.83K
Open2.76
D1 Closing2.80
Amplitude8.92%
Mkt Cap3.24M
Tradable Cap2.62M
Total Shares1.27M
T/O49.52K
T/O Rate1.84%
Tradable Shares1.02M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Pasithea Therapeutics Entered Into Sales Agreement Relating To Sale Of Shares Of Common Stock Of Up To $2.1 Million From Time To Time
Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced Cancer
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.